Eyewire News: The Podcast en Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources. https://megaphone.imgix.net/podcasts/76175cb8-6a11-11ef-a54a-87470a073a58/image/a6563563ccdf4f408d6aad7c3182e268.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Eyewire News: The Podcast no episodic Eyewire News Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources. Eyewire News: The Podcast keeps listeners updated with the latest information in the ophthalmic field, featuring breaking news from press releases, medical journals, vision publications, and other news sources.

]]> Bryn Mawr Communications (BMC) analytics@bmctoday.com Breaking News from the ASCRS Meeting in Washington DC Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 15 Apr 2026 20:39:00 -0000 full Eyewire News Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC.  Learn more about your ad choices. Visit megaphone.fm/adchoices Eyewire reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery meeting in Washington DC. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 823 More than 3 Million Bottles of Eye Drops Recalled A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; and Bausch + Lomb launches its second full range of vision IOL in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 08 Apr 2026 16:53:00 -0000 full Eyewire News A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; and Bausch + Lomb launches its second full range of vision IOL in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices A major recall is announced for several store-brand OTC eye drops; the FDA extends dosing intervals for Eylea HD in patients with Wet AMD and DME; and Bausch + Lomb launches its second full range of vision IOL in Europe.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 281 Biogen Enters GA Treatment Market After Major Acquisition Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop is commercially launched; and Kodiak Sciences releases phase 3 data for its diabetic retinopathy drug candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 01 Apr 2026 19:06:00 -0000 full Eyewire News Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop is commercially launched; and Kodiak Sciences releases phase 3 data for its diabetic retinopathy drug candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices Pharma giant Biogen announces its intention to acquire Apellis in a multi-billion dollar deal; a recently approved first-of-its-kind presbyopia drop is commercially launched; and Kodiak Sciences releases phase 3 data for its diabetic retinopathy drug candidate.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 344 Interview with ASCRS Executive Director Steve Speares The Executive Director of The American Society of Cataract & Refractive Surgery (ASCRS) previews the upcoming annual meeting and discusses the most pressing issues facing ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 25 Mar 2026 20:00:00 -0000 full Eyewire News The Executive Director of The American Society of Cataract & Refractive Surgery (ASCRS) previews the upcoming annual meeting and discusses the most pressing issues facing ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices The Executive Director of The American Society of Cataract & Refractive Surgery (ASCRS) previews the upcoming annual meeting and discusses the most pressing issues facing ophthalmology. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 701 Alcon and Lensar Call Off Merger Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 18 Mar 2026 19:31:00 -0000 full Eyewire News Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 382 FDA Agrees to Review Phentolamine for Presbyopia The FDA agrees to review a presbyopia drop designed to modulate pupil dynamics; a new endocapsular device receives clearance in Europe; and Rayner makes an acquisition to expands its cataract surgery portfolio.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 04 Mar 2026 21:07:00 -0000 full Eyewire News The FDA agrees to review a presbyopia drop designed to modulate pupil dynamics; a new endocapsular device receives clearance in Europe; and Rayner makes an acquisition to expands its cataract surgery portfolio.  Learn more about your ad choices. Visit megaphone.fm/adchoices The FDA agrees to review a presbyopia drop designed to modulate pupil dynamics; a new endocapsular device receives clearance in Europe; and Rayner makes an acquisition to expands its cataract surgery portfolio. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 691 Zeiss Launches App to Improve Workflow Zeiss releases a software app that aims to address longstanding challenges in ophthalmic care; Oertli launches its new surgical platform, the OS 4 Up, in Europe; and Harrow introduces direct-to-prescriber cash-pay kits for ophthalmic branded medications. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 25 Feb 2026 20:51:00 -0000 full Eyewire News Zeiss releases a software app that aims to address longstanding challenges in ophthalmic care; Oertli launches its new surgical platform, the OS 4 Up, in Europe; and Harrow introduces direct-to-prescriber cash-pay kits for ophthalmic branded medications. Learn more about your ad choices. Visit megaphone.fm/adchoices Zeiss releases a software app that aims to address longstanding challenges in ophthalmic care; Oertli launches its new surgical platform, the OS 4 Up, in Europe; and Harrow introduces direct-to-prescriber cash-pay kits for ophthalmic branded medications.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 233 Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 18 Feb 2026 20:08:00 -0000 full Eyewire News Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology. Learn more about your ad choices. Visit megaphone.fm/adchoices Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 362 Study: Metformin May Lower AMD Progression New research reveals that a popular diabetes treatment may lower the risk of AMD progression; a study examines the performance of large language models on specialty ophthalmology examinations; and a new doctor-led alliance that aims to support private practice optometrists has officially launched.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 11 Feb 2026 20:45:00 -0000 full Eyewire News New research reveals that a popular diabetes treatment may lower the risk of AMD progression; a study examines the performance of large language models on specialty ophthalmology examinations; and a new doctor-led alliance that aims to support private practice optometrists has officially launched.  Learn more about your ad choices. Visit megaphone.fm/adchoices New research reveals that a popular diabetes treatment may lower the risk of AMD progression; a study examines the performance of large language models on specialty ophthalmology examinations; and a new doctor-led alliance that aims to support private practice optometrists has officially launched. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 306 First Dual-Agent Eye Drop for Presbyopia Approved The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 04 Feb 2026 20:01:00 -0000 full Eyewire News The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure.  Learn more about your ad choices. Visit megaphone.fm/adchoices The FDA approves the first dual-agent eye drop for presbyopia; Rayner launches a personalized, AI-powered patient education platform; and new study examines the link between sleep positioning and eye pressure. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 445 FDA Approves Label Supplement for iDose TR The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 28 Jan 2026 20:00:00 -0000 full Eyewire News The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 337 Rayner Launches New Phaco System Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 21 Jan 2026 21:02:00 -0000 full Eyewire News Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name.  Learn more about your ad choices. Visit megaphone.fm/adchoices Rayner launches a new phaco system in the US; Eylea 8 mg is approved for a third indication in Europe; and Nanodropper announces a consolidation plan to expand its offerings under a new name. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 254 Moorfields Researchers Reveal Promising Treatment for Hypotony New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 14 Jan 2026 20:21:00 -0000 full Eyewire News New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases. Learn more about your ad choices. Visit megaphone.fm/adchoices New research may provide hope for patients with a rare vision-threatening condition; the first daily disposable soft contact lens using EDOF technology for presbyopia is cleared in the US; and there several advancements made in the clinical development of treatment candidates for retinal diseases.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 622 Staar Terminates Merger with Alcon Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 07 Jan 2026 20:41:00 -0000 full Eyewire News Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis.  Learn more about your ad choices. Visit megaphone.fm/adchoices Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 695 2025 Year in Review - Part 2 Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 31 Dec 2025 05:00:00 -0000 full Eyewire News Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 525 2025 Year in Review - Part 1 There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 24 Dec 2025 05:00:00 -0000 full Eyewire News There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 577 Update on Reproxalap PDUFA Timing Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 17 Dec 2025 20:44:00 -0000 full Eyewire News Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.  Learn more about your ad choices. Visit megaphone.fm/adchoices Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 531 New Glaucoma Technologies Advance in Clinical Development Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 10 Dec 2025 20:32:00 -0000 full Eyewire News Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant.  Learn more about your ad choices. Visit megaphone.fm/adchoices Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 307 Eylea HD Approved for RVO and Extended Dosing Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 03 Dec 2025 20:39:00 -0000 full Eyewire News Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 300 Leaders Discuss Emerging Technologies in Glaucoma Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 26 Nov 2025 16:30:00 -0000 full Eyewire News Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond.  Learn more about your ad choices. Visit megaphone.fm/adchoices Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 807 Live Coverage of B+L Investor Day Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge.  Learn more about your ad choices. Visit megaphone.fm/adchoices Tue, 18 Nov 2025 21:40:00 -0000 full Eyewire News Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge.  Learn more about your ad choices. Visit megaphone.fm/adchoices Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 419 Ryjunea Approved in the UK for Myopia Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 12 Nov 2025 20:43:00 -0000 full Eyewire News Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP. Learn more about your ad choices. Visit megaphone.fm/adchoices Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 317 Ophthalmic Executives Provide Company Updates (Part 2 of 2) Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 05 Nov 2025 16:33:00 -0000 full Eyewire News Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 918 Ophthalmic Executives Provide Company Updates (Part 1 of 2) Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 29 Oct 2025 17:29:00 -0000 full Eyewire News Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 997 Breaking News from the AAO Meeting in Orlando EyewireTV reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in Orlando. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 22 Oct 2025 20:27:00 -0000 full Eyewire News EyewireTV reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in Orlando. Learn more about your ad choices. Visit megaphone.fm/adchoices EyewireTV reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in Orlando.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1284 First Robotic Cataract Surgery Performed Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 15 Oct 2025 19:27:00 -0000 full Eyewire News Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL.  Learn more about your ad choices. Visit megaphone.fm/adchoices Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 440 Lenz Therapeutics' Vizz Commerically Launched A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 08 Oct 2025 20:04:00 -0000 full Eyewire News A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates. Learn more about your ad choices. Visit megaphone.fm/adchoices A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 387 Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 2 of 2) Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 01 Oct 2025 19:00:00 -0000 full Eyewire News Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1065 Visionary Breakthroughs: A Spotlight on Innovations in Eye Care (Part 1 of 2) Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 24 Sep 2025 20:05:00 -0000 full Eyewire News Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1100 Breaking News From the ESCRS Congress in Copenhagen EyewireTV reports on new products and breaking news live from the ESCRS Congress in Copenhagen.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 17 Sep 2025 21:23:00 -0000 full Eyewire News EyewireTV reports on new products and breaking news live from the ESCRS Congress in Copenhagen.  Learn more about your ad choices. Visit megaphone.fm/adchoices EyewireTV reports on new products and breaking news live from the ESCRS Congress in Copenhagen. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1007 Vision Advocacy Leaders Speak Out Against Proposed NEI Cuts A proposal by the Trump Administration calls for cuts to the National Institutes of Health and consolidation of the federal government’s 27 institutes into just eight. This includes folding the National Eye Institute into a new broader institute on neuroscience and brain research. Ophthalmic leaders discuss what the vision care advocacy community is doing to combat proposed cuts to the National Eye Institute.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 10 Sep 2025 18:04:00 -0000 full Eyewire News A proposal by the Trump Administration calls for cuts to the National Institutes of Health and consolidation of the federal government’s 27 institutes into just eight. This includes folding the National Eye Institute into a new broader institute on neuroscience and brain research. Ophthalmic leaders discuss what the vision care advocacy community is doing to combat proposed cuts to the National Eye Institute.  Learn more about your ad choices. Visit megaphone.fm/adchoices A proposal by the Trump Administration calls for cuts to the National Institutes of Health and consolidation of the federal government’s 27 institutes into just eight. This includes folding the National Eye Institute into a new broader institute on neuroscience and brain research. Ophthalmic leaders discuss what the vision care advocacy community is doing to combat proposed cuts to the National Eye Institute. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 910 Update on Investigational Treatments for Retinal Diseases Several companies with treatment candidates for retinal diseases provide clinical updates; Nicox releases new phase 3 data for its investigational glaucoma eye drop; the first patient is implanted with Ocumetics’ novel accommodating lens; and ASCRS provides details for its second annual Business of Refractive Cataract Surgery Summit. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 03 Sep 2025 19:48:00 -0000 full Eyewire News Several companies with treatment candidates for retinal diseases provide clinical updates; Nicox releases new phase 3 data for its investigational glaucoma eye drop; the first patient is implanted with Ocumetics’ novel accommodating lens; and ASCRS provides details for its second annual Business of Refractive Cataract Surgery Summit. Learn more about your ad choices. Visit megaphone.fm/adchoices Several companies with treatment candidates for retinal diseases provide clinical updates; Nicox releases new phase 3 data for its investigational glaucoma eye drop; the first patient is implanted with Ocumetics’ novel accommodating lens; and ASCRS provides details for its second annual Business of Refractive Cataract Surgery Summit.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 449 CE Certification for New Glaucoma Surgical Implant Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 27 Aug 2025 19:54:00 -0000 full Eyewire News Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions. Learn more about your ad choices. Visit megaphone.fm/adchoices Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions.


Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 272 Special Report: TFOS DEWS III Leaders Discuss New DED Guidance Leaders from the Tear Film and Ocular Surface Society discuss the biggest takeaways from the recently released TFOS DEWS III report. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 20 Aug 2025 16:00:00 -0000 full Eyewire News Leaders from the Tear Film and Ocular Surface Society discuss the biggest takeaways from the recently released TFOS DEWS III report. Learn more about your ad choices. Visit megaphone.fm/adchoices Leaders from the Tear Film and Ocular Surface Society discuss the biggest takeaways from the recently released TFOS DEWS III report.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 613 First Commerical Surgeries Performed with MacTel Therapy Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 13 Aug 2025 20:00:00 -0000 full Eyewire News Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad choices. Visit megaphone.fm/adchoices Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 489 Alcon Acquires Staar for $1.5 Billion Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week.   Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 06 Aug 2025 20:45:00 -0000 full Eyewire News Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week.   Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week.

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 802 Tryptyr Now Available in US Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 30 Jul 2025 20:44:00 -0000 full Eyewire News Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 294 Harrow Adds Biosimilars to US Portfolio Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 23 Jul 2025 20:46:00 -0000 full Eyewire News Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 279 AECOS Presentation Summaries Leading ophthalmologists share summaries of their presentations live from thee AECOS Summer Symposium.     Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 16 Jul 2025 20:09:00 -0000 full Eyewire News Leading ophthalmologists share summaries of their presentations live from thee AECOS Summer Symposium.     Learn more about your ad choices. Visit megaphone.fm/adchoices Leading ophthalmologists share summaries of their presentations live from thee AECOS Summer Symposium.  

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 657 Alcon Acquires LumiThera Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 09 Jul 2025 19:34:00 -0000 full Eyewire News Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management. Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon makes a major acquisition to bolster is vitreoretinal surgery portfolio; the European Commission (EC) approves Eylea 8 mg for extended treatment intervals; and Eric Donnenfeld, MD, discusses the business of myopia management.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 389 Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 02 Jul 2025 20:48:00 -0000 full Eyewire News Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia.  Learn more about your ad choices. Visit megaphone.fm/adchoices Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 311 Special Report: Update on Holland Foundation The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 25 Jun 2025 16:00:00 -0000 full Eyewire News The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease. Learn more about your ad choices. Visit megaphone.fm/adchoices The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 533 TFOS DEWS III Published The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 18 Jun 2025 20:35:00 -0000 full Eyewire News The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi. Learn more about your ad choices. Visit megaphone.fm/adchoices The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 303 First Myopia Drug Approved in Europe The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 11 Jun 2025 20:49:00 -0000 full Eyewire News The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology.  Learn more about your ad choices. Visit megaphone.fm/adchoices The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 295 Alcon Gains FDA Approval for Novel DED Drug Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 04 Jun 2025 20:42:00 -0000 full Eyewire News Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials.  Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials. 


Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 506 Special Report: Executives Discuss Overcoming Challenges Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 28 May 2025 17:50:00 -0000 full Eyewire News Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1291 B+L Launches New Scleral Lenses Technology B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe.   Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 21 May 2025 20:41:00 -0000 full Eyewire News B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe.   Learn more about your ad choices. Visit megaphone.fm/adchoices B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe.

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 232 B+L Receives Approval in Europe for LuxLife IOL Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 14 May 2025 20:13:00 -0000 full Eyewire News Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit megaphone.fm/adchoices Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions


Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 334 Ophthalmic Leaders Launch SightLine Meeting Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 07 May 2025 18:58:00 -0000 full Eyewire News Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices Commercial stakeholders discuss the challenges and opportunities in ophthalmology in this special edition of Eyewire News: The Podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 595 Breaking News from the ASCRS Meeting in Los Angeles EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 30 Apr 2025 20:11:00 -0000 full Eyewire News EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles. Learn more about your ad choices. Visit megaphone.fm/adchoices EyewireTV reports on new products and breaking news live from the American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles.


Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 869 FDA Issues CRL to Regeneron for Eylea HD Extended Dosing The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.     Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 23 Apr 2025 13:00:00 -0000 full Eyewire News The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.     Learn more about your ad choices. Visit megaphone.fm/adchoices The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.

 

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 284 Orasis Launches Presbyopia Eye Drop Qlosi A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 16 Apr 2025 18:56:00 -0000 full Eyewire News A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate. Learn more about your ad choices. Visit megaphone.fm/adchoices A presbyopia drop is officially launched in the US; Nordic Pharma receives European approval for its novel dry eye therapy; and Tenpoint submits an NDA for a presbyopia eye drop candidate.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 576 Utilizing AI to Provide DR Screening to Underserved Communities EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 09 Apr 2025 19:16:00 -0000 full Eyewire News EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations. Learn more about your ad choices. Visit megaphone.fm/adchoices EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1077 Alcon Launches PanOptix Pro in US Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 02 Apr 2025 20:13:00 -0000 full Eyewire News Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform. Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 392 Alcon Announces Plans to Acquire Lensar Alcon makes a major acquisition to bolster its cataract surgery portfolio; Opthea releases phase results for its combination wet AMD candidate; and Bausch + Lomb announces results from a phase 4 extension study of dry eye disease drug Miebo. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 26 Mar 2025 20:07:00 -0000 full Eyewire News Alcon makes a major acquisition to bolster its cataract surgery portfolio; Opthea releases phase results for its combination wet AMD candidate; and Bausch + Lomb announces results from a phase 4 extension study of dry eye disease drug Miebo. Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon makes a major acquisition to bolster its cataract surgery portfolio; Opthea releases phase results for its combination wet AMD candidate; and Bausch + Lomb announces results from a phase 4 extension study of dry eye disease drug Miebo.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 326 FDA Expands Product Label for Iluvien Iluvien receives a major label expansion; Bausch and Lomb launches a new orthokeratology lens fitting system; and several updates are announced in development wet AMD candidates.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 19 Mar 2025 20:32:00 -0000 full Eyewire News Iluvien receives a major label expansion; Bausch and Lomb launches a new orthokeratology lens fitting system; and several updates are announced in development wet AMD candidates.  Learn more about your ad choices. Visit megaphone.fm/adchoices Iluvien receives a major label expansion; Bausch and Lomb launches a new orthokeratology lens fitting system; and several updates are announced in development wet AMD candidates. 



Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 279 FDA Approves First Treatment for MacTel The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 12 Mar 2025 19:47:00 -0000 full Eyewire News The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform. Learn more about your ad choices. Visit megaphone.fm/adchoices The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 503 Haag-Streit Launches METIS 900 Microscope Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 05 Mar 2025 20:44:00 -0000 full Eyewire News Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology. Learn more about your ad choices. Visit megaphone.fm/adchoices Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 289 New Myopia Software on Pentacam AXL Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 26 Feb 2025 21:00:00 -0000 full Eyewire News Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform Learn more about your ad choices. Visit megaphone.fm/adchoices Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 279 Alcon Voyager DSLT Fully Launched in US Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 19 Feb 2025 20:54:00 -0000 full Eyewire News Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System.  Learn more about your ad choices. Visit megaphone.fm/adchoices Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 401 AAO Opposes NIH Research Funding Proposal The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 12 Feb 2025 21:09:00 -0000 full Eyewire News The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system. Learn more about your ad choices. Visit megaphone.fm/adchoices The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 348 FDA Approves Genentech's Susvimo Ocular Implant for DME The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 05 Feb 2025 21:00:00 -0000 full Eyewire News The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoices The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 310 Norlase Launches First Pattern Scanning LIO The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 29 Jan 2025 21:21:00 -0000 full Eyewire News The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchoices The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 400 Zeiss MEL 90 Approved by FDA Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 22 Jan 2025 20:33:00 -0000 full Eyewire News Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoices Zeiss receives a major approval for its new excimer laser;

Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 337 Special Report – Increasing Access to Care Through the Cure Blindness Project Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 15 Jan 2025 19:50:02 -0000 full Eyewire News Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 561 Glaukos Submits NDA for Epi-On CLX Candidate Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 08 Jan 2025 21:08:42 -0000 full Eyewire News Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit megaphone.fm/adchoices Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 331 2024 Year in Review — Part 2 In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 01 Jan 2025 05:00:00 -0000 full Eyewire News In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology. Learn more about your ad choices. Visit megaphone.fm/adchoices In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 735 2024 Year in Review — Part 1 In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout of autonomous AI screening technology; and a total solar eclipse. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 25 Dec 2024 05:00:00 -0000 full Eyewire News In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout of autonomous AI screening technology; and a total solar eclipse. Learn more about your ad choices. Visit megaphone.fm/adchoices In today’s broadcast, we look back at the top stories from the first half of 2024. There were several advancements made during the first six months., including the approval of an excimer laser platform; the global adoption of sustained-released anti-VEGF treatments for retinal diseases; the rollout of autonomous AI screening technology; and a total solar eclipse.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 687 B+L Bolsters Glaucoma Offerings with Elios Acquisition Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices.   Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 18 Dec 2024 20:55:12 -0000 full Eyewire News Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices.   Learn more about your ad choices. Visit megaphone.fm/adchoices Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices.

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 256 Phase 3 Results for Novel Sedation Tablet New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 11 Dec 2024 21:00:00 -0000 full Eyewire News New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 292 Phakic IOL for Presbyopia Approved in Europe A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 04 Dec 2024 21:00:00 -0000 full Eyewire News A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoices A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 261 Special Report: OWL Celebrates 20th Anniversary Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 27 Nov 2024 17:00:00 -0000 full Eyewire News Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary.  Learn more about your ad choices. Visit megaphone.fm/adchoices Executives from Ophthalmic World Leaders discuss the history and goals of thee organization as it celebrates its 20th anniversary. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 425 Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 20 Nov 2024 20:56:10 -0000 full Eyewire News The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 646 Ophthalmic Executives Provide Company Updates (Part 2 of 2) Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 13 Nov 2024 19:43:27 -0000 full Eyewire News Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV. Learn more about your ad choices. Visit megaphone.fm/adchoices Leaders of several ophthalmic companies with a focus on the posterior segment provide updates on their pipeline and new products in this special edition of EyewireTV.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 929 Ophthalmic Executives Provide Company Updates (Part 1 of 2) We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 06 Nov 2024 19:36:10 -0000 full Eyewire News We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development. Learn more about your ad choices. Visit megaphone.fm/adchoices We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 1905 Posterior Segment Company Updates Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 30 Oct 2024 20:26:00 -0000 full Eyewire News Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol. Learn more about your ad choices. Visit megaphone.fm/adchoices Several companies with product candidates in the posterior segment provide updates; Ocuphire acquires an ophthalmic gene therapy company; and Astellas provides an update on its regulatory plans for GA drug avacincaptad pegol.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 428 Breaking News From the AAO Meeting in Chicago Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 23 Oct 2024 20:02:22 -0000 full Eyewire News Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago. Learn more about your ad choices. Visit megaphone.fm/adchoices Eyewire News: The Podcast reports on new products and breaking news live from the American Academy of Ophthalmology meeting in Chicago.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 807 B+L Receives FDA Approval for enVista Envy IOL Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.  Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 16 Oct 2024 16:40:21 -0000 full Eyewire News Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop.  Learn more about your ad choices. Visit megaphone.fm/adchoices Bausch + Lomb receives FDA approval for a new IOL on its enVista platform; Nanoscope advances it gene therapy for retinitis pigmentosa; and Orasis completes a major funding round to support the launch of its presbyopia eye drop. 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 281 Aldeyra Resubmits NDA for DED Drug Reproxalap Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 09 Oct 2024 19:28:36 -0000 full Eyewire News Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad choices. Visit megaphone.fm/adchoices Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 280 Water-Free Ciclosporin-Based Eye Drop for DED Approved in Europe Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.    Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 02 Oct 2024 19:20:21 -0000 full Eyewire News Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.    Learn more about your ad choices. Visit megaphone.fm/adchoices Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe. 

 

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 258 Two Partnerships Formed to Advance Glaucoma Treatments Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 25 Sep 2024 19:22:38 -0000 full Eyewire News Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system. Learn more about your ad choices. Visit megaphone.fm/adchoices Two collaborations are made to develop and market new glaucoma treatments; Apellis receives feedback from a committee of thee EMA for its geographic atrophy treatment pegcetacoplan; and Topcon receives FDA clearance for OCTA on the company’s Maestro2 fundus camera system.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 281 Breaking News From the ESCRS Congress in Barcelona (Part 2 of 2) EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona. Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 18 Sep 2024 18:04:47 -0000 full Eyewire News EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona. Learn more about your ad choices. Visit megaphone.fm/adchoices EyewireTV reports on new products and breaking news live from the European Society of Cataract and Refractive Surgeons Congress in Barcelona.

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 637 Breaking News From the ESCRS Congress in Barcelona (Part 1 of 2) Zeiss Lenticule Extraction for Hyperopia • Alcon Ngenuity 1.5 • Oculus Pentacam Cornea OCT • Lensar ALLY Adaptive Cataract Treatment System • BVI Serenity IOLs • Topcon TRK-Omnia Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 11 Sep 2024 14:03:00 -0000 full Eyewire News Zeiss Lenticule Extraction for Hyperopia • Alcon Ngenuity 1.5 • Oculus Pentacam Cornea OCT • Lensar ALLY Adaptive Cataract Treatment System • BVI Serenity IOLs • Topcon TRK-Omnia Learn more about your ad choices. Visit megaphone.fm/adchoices Zeiss Lenticule Extraction for Hyperopia • Alcon Ngenuity 1.5 • Oculus Pentacam Cornea OCT • Lensar ALLY Adaptive Cataract Treatment System • BVI Serenity IOLs • Topcon TRK-Omnia

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 767 Weekly Headlines: First Therapy for Acanthamoeba Keratitis Approved in Europe First Therapy for Acanthamoeba Keratitis Approved in Europe • Oculus Adds Dual Testing Functionality to Easyfield VR • FDA Clears IND Application for Stem Cell Therapy for Primary Photoreceptor Diseases Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 04 Sep 2024 14:02:00 -0000 full Eyewire News First Therapy for Acanthamoeba Keratitis Approved in Europe • Oculus Adds Dual Testing Functionality to Easyfield VR • FDA Clears IND Application for Stem Cell Therapy for Primary Photoreceptor Diseases Learn more about your ad choices. Visit megaphone.fm/adchoices First Therapy for Acanthamoeba Keratitis Approved in Europe • Oculus Adds Dual Testing Functionality to Easyfield VR • FDA Clears IND Application for Stem Cell Therapy for Primary Photoreceptor Diseases

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 279 Weekly Headlines: Rayner Unveils First AI-Designed Spiral IOL Rayner Unveils First AI-Designed Spiral IOL • Visionix Launches VX 610 Non-Mydriatic Automated Fundus Camera • Injectsense Completes First Human Implant of Ultraminiature IOP Sensor Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 28 Aug 2024 16:39:00 -0000 full Eyewire News Rayner Unveils First AI-Designed Spiral IOL • Visionix Launches VX 610 Non-Mydriatic Automated Fundus Camera • Injectsense Completes First Human Implant of Ultraminiature IOP Sensor Learn more about your ad choices. Visit megaphone.fm/adchoices Rayner Unveils First AI-Designed Spiral IOL • Visionix Launches VX 610 Non-Mydriatic Automated Fundus Camera • Injectsense Completes First Human Implant of Ultraminiature IOP Sensor

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 256 no Weekly Headlines: Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations • Ultrasonic Sensor Device Launched for Loss of Side Vision • Ocuvex Therapeutics Acquires Visiox Pharmaceuticals Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 21 Aug 2024 16:39:00 -0000 full Eyewire News Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations • Ultrasonic Sensor Device Launched for Loss of Side Vision • Ocuvex Therapeutics Acquires Visiox Pharmaceuticals Learn more about your ad choices. Visit megaphone.fm/adchoices Gene Therapies for IRDs Receive FDA Rare Pediatric Disease Designations • Ultrasonic Sensor Device Launched for Loss of Side Vision • Ocuvex Therapeutics Acquires Visiox Pharmaceuticals

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 293 no Weekly Headlines: Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 14 Aug 2024 16:39:00 -0000 full Eyewire News Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop Learn more about your ad choices. Visit megaphone.fm/adchoices Aldeyra Reports New Phase 3 Data for DED Drug Candidate Reproxalap • Lensar Receives European Approval for ALLY System • Lenz Therapeutics Submits NDA for Presbyopia Eye Drop

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 317 no Weekly Headlines: Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin • Wearable Aid with AI-Powered Visual Assistant is Unveiled • ASCRS Business of Refractive Cataract Surgery Summit Launched Learn more about your ad choices. Visit megaphone.fm/adchoices Wed, 07 Aug 2024 16:38:00 -0000 full Eyewire News Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin • Wearable Aid with AI-Powered Visual Assistant is Unveiled • ASCRS Business of Refractive Cataract Surgery Summit Launched Learn more about your ad choices. Visit megaphone.fm/adchoices Two Phase 3 Trials for Dry and Wet AMD Drug Candidates Begin • Wearable Aid with AI-Powered Visual Assistant is Unveiled • ASCRS Business of Refractive Cataract Surgery Summit Launched

Learn more about your ad choices. Visit megaphone.fm/adchoices

]]> 360 no